Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:SLXP
- CUSIP: 79543510
- Web: N/A
- 50 Day Moving Avg: $163.00
- 200 Day Moving Avg: $136.00
- 52 Week Range: $86.00 - $173.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 18.78
- P/E Growth: 0
- Average Volume: 3.35 million shs.
Frequently Asked Questions for Salix Pharmaceuticals (NASDAQ:SLXP)
What is Salix Pharmaceuticals' stock symbol?
Salix Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLXP."
How were Salix Pharmaceuticals' earnings last quarter?
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) posted its earnings results on Monday, March, 2nd. The company reported ($2.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $2.32. The business had revenue of $13 million for the quarter, compared to analyst estimates of $187.97 million. During the same quarter in the previous year, the company earned $1.06 EPS. View Salix Pharmaceuticals' Earnings History.
Who are some of Salix Pharmaceuticals' key competitors?
Some companies that are related to Salix Pharmaceuticals include Ampio Pharmaceuticals (AMPE), Pernix Therapeutics Holdings (PTX), Allergan plc (ACT), Auxilium Pharmaceuticals (AUXL), Avanir Pharmaceuticals (AVNR), Cadence Pharmaceuticals (CADX), Forest Laboratories (FRX), Hi-Tech Pharmacal (HITK), Optimer Pharmaceuticals (OPTR), Questcor Pharmaceuticals (QCOR), Santarus (SNTS), Shire Viropharma (VPHM) and Warner Chilcott Plc (WCRX).
How do I buy Salix Pharmaceuticals stock?
Shares of Salix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Salix Pharmaceuticals stock cost?
One share of Salix Pharmaceuticals stock can currently be purchased for approximately $169.00.
Consensus Ratings for Salix Pharmaceuticals (NASDAQ:SLXP) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Salix Pharmaceuticals (NASDAQ:SLXP)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Salix Pharmaceuticals (NASDAQ:SLXP)Earnings History by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/2/2015||Q414||($0.29)||($2.61)||$187.97 million||$13.00 million||View||N/A|
|11/6/2014||Q314||$1.56||$1.53||$394.00 million||$354.70 million||View||N/A|
|8/7/2014||Q214||$1.69||$1.59||$397.06 million||$382.00 million||View||Listen|
|5/8/2014||Q114||$0.91||$1.05||$372.91 million||$384.00 million||View||Listen|
|2/27/2014||Q413||$0.93||$1.06||$247.29 million||$257.60 million||View||Listen|
|11/7/2013||Q313||$0.86||$0.89||$239.70 million||$238.20 million||View||N/A|
|8/8/2013||Q2 2013||$0.81||$0.87||$226.34 million||$235.40 million||View||Listen|
|5/9/2013||Q1 2013||$0.67||$0.63||$205.94 million||$202.60 million||View||Listen|
|2/28/2013||Q4 2012||$0.78||$0.81||$199.41 million||$198.17 million||View||N/A|
|11/7/2012||Q312||$0.69||$0.95||$187.23 million||$185.13 million||View||N/A|
Earnings Estimates for Salix Pharmaceuticals (NASDAQ:SLXP)
Current Year EPS Consensus Estimate: $4 EPS
Next Year EPS Consensus Estimate: $9 EPS
Dividend History for Salix Pharmaceuticals (NASDAQ:SLXP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Salix Pharmaceuticals (NASDAQ:SLXP)Insider Trades by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/6/2015||Timothy J Creech||Insider||Sell||4,600||$157.67||$725,282.00|| |
|3/6/2015||William P Forbes||EVP||Sell||20,000||$157.96||$3,159,200.00|| |
|11/12/2014||William P Forbes||EVP||Sell||11,079||$95.05||$1,053,058.95|| |
|6/26/2014||Carolyn J Logan||CEO||Sell||53,057||$123.38||$6,546,172.66|| |
|4/22/2014||Alonzo Thomas D||Director||Sell||11,530||$110.89||$1,278,561.70|| |
|1/10/2014||Alonzo Thomas D||Director||Sell||12,050||$91.83||$1,106,551.50|| |
|1/9/2014||Adam Derbyshire||CFO||Sell||30,001||$91.48||$2,744,491.48|| |
|1/8/2014||William Forbes||EVP||Sell||8,000||$90.06||$720,480.00|| |
|1/7/2014||Rick Scruggs||EVP||Sell||8,463||$88.31||$747,367.53|| |
|1/7/2014||William Keane||Director||Sell||22,500||$88.31||$1,986,975.00|| |
|7/24/2013||William P Forbes||EVP||Sell||12,000||$70.93||$851,160.00|| |
|4/10/2013||William P Forbes||EVP||Sell||8,673||$49.37||$428,186.01|| |
|12/26/2012||Adam C Derbyshire||CFO||Sell||60,000||$41.44||$2,486,400.00|| |
|11/13/2012||Mark A Sirgo||Director||Sell||3,450||$40.53||$139,828.50|| |
Headline Trends for Salix Pharmaceuticals (NASDAQ:SLXP)
Latest Headlines for Salix Pharmaceuticals (NASDAQ:SLXP)
Salix Pharmaceuticals (SLXP) Chart for Wednesday, May, 24, 2017